Vera Therapeutics (VERA) has released an update to notify the public and investors about a regulation fd disclosure.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Vera Therapeutics, Inc. announced positive 72-week results from the open label extension of its Phase 2b ORIGIN clinical trial, which evaluated the efficacy of atacicept in treating patients with immunoglobulin A nephropathy. Alongside the announcement, the company released a presentation detailing the trial’s findings.
For further insights into VERA stock, check out TipRanks’ Stock Analysis page.